Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

Author： Parker E.   Van Heek M.   Stamford A.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.440, Iss.2, 2002-04, pp. : 173-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status

By  

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 11, 2014-10 ,pp. : 896-919

Bentham Science Publishers

Access to resources Recommend Favorite

Orlistat: its current status as an anti-obesity drug

By Ballinger A.   Peikin S.R.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 109-117

Elsevier

Access to resources Recommend Favorite

Neuropeptide Y receptors as targets of obesity treatment

By Ishihara PhD Akane   Moriya PhD Minoru   MacNeil PhD Douglas J   Fukami PhD Takehiro   Kanatani PhD Akio  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 12, 2006-12 ,pp. : 1701-1712

Informa Healthcare

Access to resources Recommend Favorite

Anti-obesity drug development

By Bays Harold   Dujovne Carlos  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 9, 2002-09 ,pp. : 1189-1204

Informa Healthcare

Access to resources Recommend Favorite

Sibutramine: current status as an anti-obesity drug and its future perspectives

By Sharma Bikash   Henderson David C  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 12, 2008-08 ,pp. : 2161-2173

Informa Healthcare

Access to resources Recommend Favorite